Efficacy of gemcitabine combined with cisplatin chemotherapy in the treatment of recurrent triple negative breast cancer after anthracycline and taxanes treatment
Objective To explore the clinical efficacy of gemcitabine combined with cisplatin chemotherapy in the treatment of patients with recurrent triple negative breast cancer(TNBC)after anthracycline and taxanes treatment and its influence on tumor markers.Methods A total of 61 patients with recurrent TNBC after anthracycline and taxanes treatment,who were admitted to the Department of Breast Surgery,Hebei Petro China Central Hospital from January 2020 to January 2021,were selected as the research subjects.The patients were divided into observation group(n=31)and control group(n=30)according to different chemotherapy schemes.The patients in the observation group were given gemcitabine combined with cisplatin chemotherapy,while the patients in the control group were given vinorelbine combined with cisplatin chemotherapy.Patients in both groups were treated for 4 continuous cycles(21 days each cycle).The clinical efficacy of patients between the two groups after treatment was compared.Before treatment and after 4 cycles of treatment,5 mL of fasting peripheral venous blood was taken from patients in the two groups,and the serum levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and thymidine kinase 1(TK1)were detected by using the enzyme-linked immunosorbent assay.The adverse reactions of patients in the two groups were recorded,including nausea and vomiting,diarrhea,leukopenia,thrombocytopenia,erythropenia,liver function damage and renal function damage,and the incidence of adverse reactions was compared.The overall 3-year survival rate of patients in the two groups was compared.Results The objective remission rate(ORR)and disease control rate(DCR)of patients in the control group were 26.67％(8/30)and 60.00％(18/30),respectively.The ORR and DCR of patients in the observation group were 51.61％(16/31)and 83.87％(26/31),respectively.The ORR and DCR of patients in the observation group were significantly higher than those in the control group(x2=3.976,4.322;P＜0.05).There was no statistically significant difference in serum CEA,CA125 and TK1 levels between the two groups before treatment(P＞0.05).The serum CEA,CA125 and TK1 levels of patients in the two groups after treatment were significantly lower those before treatment(P＜0.05).After treatment,the serum CEA,CA125 and TK1 levels of patients in the observation group were significantly lower than those in the control group(P＜0.05).The incidences of thrombocytopenia and renal function damage in patients in the observation group were significantly lower than those in the control group(x2=4.546,5.088;P＜0.05).There was no statistically significant difference in the incidence of other adverse reactions between the two groups(P＞0.05).Conclusion Gemcitabine combined with cisplatin chemotherapy is effective in the treatment of patients with recurrent TNBC after anthracycline and taxanes treatment,which can effectively regulate the level of tumor markers,reduce the incidence of adverse reactions and improve the survival rate of patients.
gemcitabinecisplatinrecurrent triple negative breast cancerclinical efficacytumor markerssurvival rate
维普
万方数据
